Literature DB >> 21478162

Lipoprotein(a) levels, apo(a) isoform size, and coronary heart disease risk in the Framingham Offspring Study.

Stefania Lamon-Fava1, Santica M Marcovina, John J Albers, Hal Kennedy, Carl Deluca, Charles C White, L Adrienne Cupples, Judith R McNamara, Leo J Seman, Vanina Bongard, Ernst J Schaefer.   

Abstract

The aim of this study was to assess the independent contributions of plasma levels of lipoprotein(a) (Lp(a)), Lp(a) cholesterol, and of apo(a) isoform size to prospective coronary heart disease (CHD) risk. Plasma Lp(a) and Lp(a) cholesterol levels, and apo(a) isoform size were measured at examination cycle 5 in subjects participating in the Framingham Offspring Study who were free of CHD. After a mean follow-up of 12.3 years, 98 men and 47 women developed new CHD events. In multivariate analysis, the hazard ratio of CHD was approximately two-fold greater in men in the upper tertile of plasma Lp(a) levels, relative to those in the bottom tertile (P < 0.002). The apo(a) isoform size contributed only modestly to the association between Lp(a) and CHD and was not an independent predictor of CHD. In multivariate analysis, Lp(a) cholesterol was not significantly associated with CHD risk in men. In women, no association between Lp(a) and CHD risk was observed. Elevated plasma Lp(a) levels are a significant and independent predictor of CHD risk in men. The assessment of apo(a) isoform size in this cohort does not add significant information about CHD risk. In addition, the cholesterol content in Lp(a) is not a significant predictor of CHD risk.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21478162      PMCID: PMC3090239          DOI: 10.1194/jlr.M012526

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  34 in total

1.  The structure of haplotype blocks in the human genome.

Authors:  Stacey B Gabriel; Stephen F Schaffner; Huy Nguyen; Jamie M Moore; Jessica Roy; Brendan Blumenstiel; John Higgins; Matthew DeFelice; Amy Lochner; Maura Faggart; Shau Neen Liu-Cordero; Charles Rotimi; Adebowale Adeyemo; Richard Cooper; Ryk Ward; Eric S Lander; Mark J Daly; David Altshuler
Journal:  Science       Date:  2002-05-23       Impact factor: 47.728

2.  First WHO/IFCC International Reference Reagent for Lipoprotein(a) for Immunoassay--Lp(a) SRM 2B.

Authors:  Francesco Dati; Jillian R Tate; Santica M Marcovina; Armin Steinmetz
Journal:  Clin Chem Lab Med       Date:  2004       Impact factor: 3.694

3.  Serum lipids, lipoprotein(a) level, and apolipoprotein(a) isoforms as prognostic markers in patients with coronary heart disease.

Authors:  U Lundstam; J Herlitz; T Karlsson; T Lindén; O Wiklund
Journal:  J Intern Med       Date:  2002-02       Impact factor: 8.989

4.  Serum lipoprotein(a) concentrations and apolipoprotein(a) isoforms: association with the severity of clinical presentation in patients with coronary heart disease.

Authors:  C S Katsouras; S A Karabina; A P Tambaki; J A Goudevenos; L K Michalis; L D Tsironis; C S Stroumbis; M S Elisaf; D A Sideris; A D Tselepis
Journal:  J Cardiovasc Risk       Date:  2001-10

Review 5.  Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal models.

Authors:  Michael B Boffa; Santica M Marcovina; Marlys L Koschinsky
Journal:  Clin Biochem       Date:  2004-05       Impact factor: 3.281

6.  Analysis of the apo(a) size polymorphism in Asian Indian populations: association with Lp(a) concentration and coronary heart disease.

Authors:  F S Geethanjali; Kalpana Luthra; Arno Lingenhel; A S Kanagasaba-Pathy; Jose Jacob; Lalit M Srivastava; Suman Vasisht; Hans-Georg Kraft; Gerd Utermann
Journal:  Atherosclerosis       Date:  2003-07       Impact factor: 5.162

Review 7.  Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality.

Authors:  Sebhat Erqou; Stephen Kaptoge; Philip L Perry; Emanuele Di Angelantonio; Alexander Thompson; Ian R White; Santica M Marcovina; Rory Collins; Simon G Thompson; John Danesh
Journal:  JAMA       Date:  2009-07-22       Impact factor: 56.272

8.  Lp(a) particles mold fibrin-binding properties of apo(a) in size-dependent manner: a study with different-length recombinant apo(a), native Lp(a), and monoclonal antibody.

Authors:  Chantal Kang; Miguel Dominguez; Stéphane Loyau; Toshiyuki Miyata; Vincent Durlach; Edouard Anglés-Cano
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-07-01       Impact factor: 8.311

9.  Genetically elevated lipoprotein(a) and increased risk of myocardial infarction.

Authors:  Pia R Kamstrup; Anne Tybjaerg-Hansen; Rolf Steffensen; Børge G Nordestgaard
Journal:  JAMA       Date:  2009-06-10       Impact factor: 56.272

10.  Apolipoprotein(a) size and lipoprotein(a) concentration and future risk of angina pectoris with evidence of severe coronary atherosclerosis in men: The Physicians' Health Study.

Authors:  Nader Rifai; Jing Ma; Frank M Sacks; Paul M Ridker; Wendy Jade L Hernandez; Meir J Stampfer; Santica M Marcovina
Journal:  Clin Chem       Date:  2004-05-20       Impact factor: 8.327

View more
  24 in total

Review 1.  Lipoprotein (a) measurements for clinical application.

Authors:  Santica M Marcovina; John J Albers
Journal:  J Lipid Res       Date:  2015-12-04       Impact factor: 5.922

2.  HDL-C, ABCA1-mediated cholesterol efflux, and lipoprotein(a): insights into a potential novel physiologic role of lipoprotein(a).

Authors:  Calvin Yeang; Sotirios Tsimikas
Journal:  J Lipid Res       Date:  2015-05-26       Impact factor: 5.922

3.  [Multiple thrombophilic risk markers in patients ≺65 years of age with retinal vein occlusion].

Authors:  C Kuhli-Hattenbach; P Hellstern; W Miesbach; T Kohnen; L-O Hattenbach
Journal:  Ophthalmologe       Date:  2017-12       Impact factor: 1.059

4.  The Prevalence and Predictors of Depression in Type 2 Diabetic Population of Punjab.

Authors:  Shallu Khullar; Harjot Dhillon; Gurpreet Kaur; Ritu Sharma; Kanchan Mehta; Rohit Aggarwal; Monica Singh; Puneetpal Singh
Journal:  Community Ment Health J       Date:  2016-01-02

5.  Biomarkers and degree of atherosclerosis are independently associated with incident atherosclerotic cardiovascular disease in a primary prevention cohort: The ARIC study.

Authors:  Anandita Agarwala; Salim Virani; David Couper; Lloyd Chambless; Eric Boerwinkle; Brad C Astor; Ron C Hoogeveen; Joe Coresh; A Richey Sharrett; Aaron R Folsom; Tom Mosley; Christie M Ballantyne; Vijay Nambi
Journal:  Atherosclerosis       Date:  2016-08-25       Impact factor: 5.162

6.  Distinct metabolism of apolipoproteins (a) and B-100 within plasma lipoprotein(a).

Authors:  Margaret R Diffenderfer; Stefania Lamon-Fava; Santica M Marcovina; P Hugh R Barrett; Julian Lel; Gregory G Dolnikowski; Lars Berglund; Ernst J Schaefer
Journal:  Metabolism       Date:  2015-11-06       Impact factor: 8.694

Review 7.  Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease?

Authors:  Michael B Boffa; Marlys L Koschinsky
Journal:  J Lipid Res       Date:  2015-12-08       Impact factor: 5.922

8.  Therapeutic potential of mipomersen in the management of familial hypercholesterolaemia.

Authors:  Carmen Gelsinger; Elisabeth Steinhagen-Thiessen; Ursula Kassner
Journal:  Drugs       Date:  2012-07-30       Impact factor: 9.546

9.  Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes).

Authors:  John J Albers; April Slee; Kevin D O'Brien; Jennifer G Robinson; Moti L Kashyap; Peter O Kwiterovich; Ping Xu; Santica M Marcovina
Journal:  J Am Coll Cardiol       Date:  2013-08-21       Impact factor: 24.094

10.  Population and assay thresholds for the predictive value of lipoprotein (a) for coronary artery disease: the EPIC-Norfolk Prospective Population Study.

Authors:  Rutger Verbeek; S Matthijs Boekholdt; Robert M Stoekenbroek; G Kees Hovingh; Joseph L Witztum; Nicholas J Wareham; Manjinder S Sandhu; Kay-Tee Khaw; Sotirios Tsimikas
Journal:  J Lipid Res       Date:  2016-01-31       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.